|
 |
BosentanThis page contains recent news articles, when available, and an overview of Bosentan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Bosentan (ET-1 receptor antagonist) improves pulmonary hemodynamics, exercise limitation, and disease severity in IPAH. We hypothesized that bosentan might ... 7thSpace Interactive (press release) Actelion Shares Sink On Almorexant Safety Woes - Dec 21, 2009 Investors' focus will now turn to another late-stage trial for Tracleer, generically known as bosentan, to treat idiopathic pulmonary fibrosis, ... Wall Street Journal Actelion "buy" - Dec 23, 2009 Demnächst stünden Daten zu Bosentan bei idiopathischer pulmonaler Fibrose an. Die Erfolgschancen bei Almorexant schätze man auf 35% und bei Bosentan auf 75% ... boerse.de (Pressemitteilung) Tedavi Yardımına Ä°liÅŸkin Uygulama TebliÄŸi (Sıra No: 14) - Dec 9, 2009 ...bendinin baÅŸlığı, “Pulmoner hipertansiyonda ıloprost trometamol (inhaler formu), bosentan ve sildenafil kullanım ilkeleriâ€? olarak deÄŸiÅŸtirilmiÅŸtir. ... Memurlar Bosentan Improves Cardiovascular Parameters in Patients With Pulmonary ... - Nov 9, 2009 Patients with persistent PH (not reversible during oxygen administration) were randomised to receive placebo plus conventional treatment or to bosentan 125 ... DG News Battling Josh Frank, 8, our bravest heart - Nov 7, 2009 To treat it doctors put Josh on a drug called Bosentan. ``It was very experimental treatment,'' Mrs Frank said. ``We had to get special approval through the ... Sunday Times.au Tracleer drives Actelion sales up 22% - Oct 20, 2009 ...while revenues climbed 22% to 1.30 billion francs, the majority of which came from Tracleer (bosentan), for pulmonary arterial hypertension. ... Pharma Times Pirfenidone NDA Filed; Partner Overseas May Woo InterMune - Nov 10, 2009 ...treatments for IPF have early stage compounds, while Swiss biotech Actelion Ltd. has experimental IPF drug bosentan (Tracleer) that is in Phase III. ... Therapeutics Daily (press release) (registration) Actelion Pharmaceuticals Ltd (CH) - Actelion announces 9-month financial ... - Oct 21, 2009 Product sales During the first nine months of 2009, Tracleer® (bosentan) sales were CHF1,114.7 million (9M 2008: CHF 945.8 m). ... PharmaLive.com (press release) Gilead Sciences, Inc. Q3 2009 Earnings Call Transcript - Oct 20, 2009 Thus, we continue to believe we have a best-in-class ERA for PAH with a distinctive profile from the sulfonamide structure ERA's, namely bosentan and ... Seeking Alpha (blog) 'What gives them the right to put a price on my life?' - Oct 30, 2009 Dr. Davis switched her to a tandem of two oral medications: Bosentan, which can aid blood flow to the lungs, and Sildenafil, which expands blood vessels (a ... Globe and Mail Actelion: 3Q09 insgesamt erwartungsgemäss - Oct 20, 2009 Klinische Daten der Phase III für Bosentan (Tracleer) bei idiopathischer pulmonaler Fibrose werden weiterhin für Anfang 2010 erwartet. ... Godmodetrader Finanznachrichten GSK va a poner en marcha un innovador estudio en hipertensión arterial ... - Nov 12, 2009 Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27(5):589-595. 6 Barst RJ, McGoon M, ... acceso.com (Comunicado de prensa) AUSBLICK/Actelion Q3: Reingewinn zwischen 97,4 und 131,4 Mio CHF erwartet - Oct 19, 2009 Im August erhielt Actelion von der US-Gesundheitsbehörde FDA die Zulassung für Tracleer (Bosentan) zur Behandlung von Patienten mit leichteren Symptomen der ... Handelszeitung Online … of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects - Oct 4, 2006 Healthy male subjects received bosentan 125 mg bid for 6.5 days in the presence ... Rifampin potently inhibited the uptake of bosentan into cells expressing ... Nature.com Bloomberg Printer-Friendly Page - Jun 20, 2008 In contrast, treatment with bosentan significantly delayed PAH progression ... The findings of EARLY indicate that treatment with bosentan may be beneficial ... Bloomberg Actelion Ltd.: Bosentan Studies In Pulmonary Fibrosis Show No Effect... - Nov 28, 2005 ALLSCHWIL, Switzerland, Nov. 28, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) today announced that in the BUILD program with bosentan ... primezone.com Cialis May Help Ease Pulmonary Hypertension - Oct 27, 2008 For the study, Barst's team randomly assigned 405 pulmonary hypertension patients to Cialis or placebo once a day, or to Cialis and bosentan (Tracleer) a ... Forbes New data backs wider use of flagship Actelion drug - Sep 2, 2007 Nazzareno Galie, a cardiologist at the University of Bologna in Italy, said the drug, known generically as bosentan, helped stabilise the condition of ... Reuters Bosentan for inoperable chronic thromboembolic pulmonary hypertension... - Sep 5, 2007 Bosentan may be an option for “no optionâ€? patients with chronic thromboembolic pulmonary hypertension (CTEPH). In a group of 157 inoperable, ... Cardiosource Bosentan (Tracleer) Improves Symptoms in Patients With Eisenmenger's ... - Nov 1, 2005 By Ed Susman. MONTREAL, CANADA -- November 1, 2005 -- The dual endothelin receptor antagonist bosentan helped improve symptoms among patients suffering from ... DG News DJ HUGIN NEWS/Bosentan (Tracleer®) receives positive EU opinion for … - Jun 27, 2008 Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ... financial.de Bosentan (Systemic).(Drug overview) - Aug 1, 2006 Bosentan (BOH-sen-tan) is used to treat the symptoms of pulmonary arterial hypertension. This is the high blood pressure that occurs in the main artery that ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … Therapy With Inhaled Iloprost and Bosentan Effective in Pulmonary ... - Nov 3, 2005 By Amanda Strong. MONTREAL, CANADA -- November 3, 2005 -- Inhaled iloprost can be safely added to bosentan and provides additional efficacy compared with ... DG News Bosentan (Tracleer) Receives EU Approval for Reduction of Number of … - Jun 11, 2007 ALLSCHWIL, Switzerland, June 11, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the European Commission has granted marketing ... wcbstv.com Long-term treatment with bosentan improves outcomes in pulmonary … - Jan 26, 2005 Pulmonary arterial hypertension (PAH) is a devastating disease that carries a poor prognosis. Untreated, about half of patients die within two years. ... Medical News Today - Medical News Today (press release) ESC: Bosentan (Tracleer) Slows Progression of Pulmonary Arterial … - Sep 5, 2007 By Ed Susman, Contributing Writer, MedPage Today. VIENNA, Sept. 5 -- For patients in the early stages of pulmonary arterial hypertension, ... MedPage Today Tracleer Linked to Rare Cases of Hepatoxicity - Mar 2, 2006 After approximately 1 year of bosentan therapy at the recommended dose, the patient's ... Bosentan is indicated for the treatment of pulmonary arterial ... Medscape Tracleer® (bosentan) receives EU approval for treatment of patients... - Aug 4, 2008 ALLSCHWIL/BASEL, SWITZERLAND - 04 August 2008 - Actelion Ltd (SWX: ATLN) announced today that Tracleer® (bosentan), a dual endothelin receptor antagonist, ... webwire.com Are endothelin-receptor antagonists the preferred treatment for PAH … - Dec 28, 2006 ...(2006) Bosentan treatment for pulmonary arterial hypertension related to connective ... Bosentan has been approved for the treatment of pulmonary arterial ... Nature.com Learn about Bosentan from Consumer Reports Health. - Jan 4, 2005 For female patients: Do not take bosentan if you are pregnant or plan to become pregnant. Bosentan ... Full Alert. Bosentan is used to treat pulmonary ... consumerreports.org Early and benefit: bosentan beneficial in patients with early PAH and... - Oct 1, 2007 Patients with early-stage pulmonary arterial hypertension (PAH) and those with either inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or ... Free with registration - Formulary - AccessMyLibrary.com Bloomberg Printer-Friendly Page - Jun 1, 2008 He also participated in the characterization of renin inhibitors as well as several endothelin receptor antagonists such as bosentan and clazosentan. ... Bloomberg … for Morbidity/Mortality Study With Bosentan in Idiopathic Pulmonary - May 30, 2006 As previously communicated in November 2005, bosentan did not have a positive ... The use of bosentan in the study was well tolerated with no unexpected ... DG News OnMedica - News: Actelion's flagship drug Tracleer (bosentan) is safe... - Sep 6, 2005 We hope you have enjoyed your visit so far. We notice that you're not currently an onmedica.com member. Would you like to join? Tell me more... ... OnMedica Bosentan for Inoperable Chronic Thromboembolic Pulmonary … - Sep 14, 2007 By Chris Berrie. VIENNA, AUSTRIA -- September 14, 2007 -- The dual endothelin receptor antagonist bosentan provides significantly improved haemodynamics and ... DG News Sitaxsentan Tops Bosentan as Pulmonary Hypertension Treatment: … - Jun 2, 2006 By Jill Stein. SAN DIEGO, CA -- June 2, 2006 -- The investigational oral, once-daily selective endothelin A receptor antagonist sitaxsentan appears to ... DG News Bosentan Side Effects from Consumer Reports Health. - Jan 4, 2005 For female patients: Do not take bosentan if you are pregnant or plan to become pregnant. Bosentan ... Full Alert. Do not take bosentan if you are pregnant ... consumerreports.org Tracleer (Bosentan) Receives New Indication In Patients With Systemic... - Apr 29, 2008 DUs are a frequent, extremely painful and disabling complication of SSc2, caused by a reduced blood flow to the fingers and toes. ... Medical News Today - Medical News Today (press release) Bosentan blocks scleroderma ulcers; does not hasten healing.( … - Feb 1, 2006 SAN DIEGO -- A second randomized clinical trial has confirmed that treatment with bosentan can help prevent the formation of digital ulcers in patients with ... Free with registration - Skin & Allergy News - AccessMyLibrary.com Actelion Provides Update on Bosentan in Japan - Feb 28, 2005 ALLSCHWIL, Switzerland, Feb. 28, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced that is has received written confirmation that the drug ... RedOrbit Bosentan label change delineates cirrhosis risk.(Clinical Rounds) - Sep 1, 2006 ROCKVILLE, MD. -- The postmarketing safety program in place for the pulmonary arterial hypertension drug bosentan recently resulted in a label change that ... Free with registration - Skin & Allergy News - AccessMyLibrary.com Bosentan Improves Quality Of Life For Patients With Pulmonary … - Jul 20, 2008 Recent studies have shown that bosentan therapy greatly improves the quality of life for patients with pulmonary arterial hypertension (PAH). ... Medical News Today - Medical News Today (press release) The Effect of Bosentan on Matrix Metalloproteinase-9 Levels in... - May 10, 2005 Objective: Systemic sclerosis (SSc) is an autoimmune disease that can potentially involve all tissues and organs of the human body. ... RedOrbit Article: Bosentan slows progression in class II PAH.(Cardiovascular … - Nov 1, 2007 Bosentan slows progression in class II PAH.(Cardiovascular Medicine)(pulmonary arterial hypertension)(Clinical report) ... find Internal Medicine News ... Pay-Per-View - Internal Medicine News - HighBeam Research … surveillance system confirms Bosentan's safety.(Cardiovascular... - Feb 1, 2006 Although regulators approved bosentan on the grounds that its ... The mean time on bosentan before liver enzyme abnormalities occurred was 127 days in the ... Free with registration - Family Practice News - AccessMyLibrary.com Encysive Pharmaceuticals Inc. Announces Top Line Data From STRIDE-2 … - Sep 14, 2005 Upon completion of STRIDE-2 patients from the Thelin 100 mg and bosentan arms ... Premature discontinuations from STRIDE-2's bosentan or Thelin 100 mg arms ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Mild PAH improved by early treatment with bosentan - Jul 18, 2008 While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit ... Gerson Lehrman Group Bosentan Improves Exercise Tolerance and Tei Index in Patients With … - Aug 23, 2005 Study objective: Pulmonary arterial hypertension (PAH) is a progressive disease with a bad prognosis. Prostanoids are well established in the medical ... RedOrbit Effect of bosentan on skin fibrosis in patients with systemic... - Feb 1, 2007 The purpose of this study is to evaluate the effect of bosentan treatment ... Condition Intervention Phase Systemic Scleroderma Drug: Bosentan Phase II Skin ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com Effect of the endothelin receptor antagonist bosentan on chronic... - Oct 20, 2006 Previous experiments have repeatedly demonstrated that exposure to chronic hypoxia (CH) elicits remarkable structural changes and chemosensory ... AJP-Lung Physiology (subscription) Bosentan in metastatic melanoma.(PIPELINE PREVIEWS)(Drug overview … - Feb 1, 2008 Actelion Ltd recently revealed preliminary data from a study of bosentan for the treatment of metastatic melanoma. Bosentan (Tracleer[R]) is an endothelin ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com Effect of bosentan on skin fibrosis in patients with systemic... - Jun 1, 2007 The purpose of this study is to evaluate the effect of bosentan treatment on ... Condition Intervention Phase Systemic Scleroderma Drug: Bosentan (Tracleer) ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com Sitaxsentan better tolerated than bosentan as oral PAH therapy.( … - Aug 15, 2005 Unlike twice-daily bosentan, sitaxsentan can be given once daffy because it is ... Overall, 35 of the patients in the study had discontinued bosentan ... Free with registration - Family Practice News - AccessMyLibrary.com Bosentan slows progression of class II PAH.(Cardiovascular Medicine)(... - Oct 15, 2007 Bosentan slows progression of class II PAH.(Cardiovascular Medicine)(Clinical report) ... find Family Practice News articles. Pay-Per-View - Family Practice News - HighBeam Research Sitaxsentan more effective than bosentan as PAH therapy.(pulmonary … - Jan 1, 2006 Sitaxsentan, a highly selective endothelin-A (ET-A) receptor antagonist undergoing FDA review as an alternative to bosentan for pulmonary arterial ... Free with registration - Formulary - AccessMyLibrary.com bosentan Actelion clinical data (phase III).(Actelion Pharmaceuticals... - Aug 15, 2005 On 9 August 2005 Actelion reported results from a double-blind, placebo-controlled, randomized, multicenter phase III study of bosentan (TRACLEER) in the ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Clinical Trials; Bosentan therapy in patients with Eisenmenger... - Aug 29, 2006 ..."The Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 ... Compared with placebo, bosentan reduced pulmonary vascular resistance index (-472.0 ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Encysive Stock Moves Up 12 Percent On Thelin Data - Feb 15, 2005 Tracleer (bosentan) therapy served as the control arm of the trial. ... The 50-mg dose of Thelin and bosentan did not reach statistical significance. ... BioWorld Online - BioWorld Online Pivotal Pulmonary Arterial Hypertension Study Concludes That Early … - Sep 23, 2008 The findings of EARLY indicate that treatment with bosentan may be beneficial for ... In EARLY, bosentan (Tracleer ® ) prevented clinical deterioration by ... marketwire.com Bosentan label revised to include liver function monitoring. - Apr 1, 2006 Actelion and the FDA have notified health care professionals of changes to the bosentan (Tracleer) prescribing information based on cases of hepatotoxity ... Free with registration - Drug Formulary Review - AccessMyLibrary.com Article: Bosentan boosts key functions in sclerosis patients.(Clinical... - Jan 1, 2007 Bosentan boosts key functions in sclerosis patients.(Clinical Rounds)(treating sclerosis patients)(Brief article) ... find Skin & Allergy News articles. Pay-Per-View - Skin & Allergy News - HighBeam Research … Highlights Clinical Data about Bosentan In Systemic Sclerosis... - Nov 22, 2005 SAN DIEGO, CA -- November 22, 2005 -- Actelion Ltd. announced the poster presentation at the American College of Rheumatology (ACR) of results of RAPIDS-2, ... DG News … Highlights Clinical Data About bosentan In Systemic Sclerosi - Nov 16, 2005 In terms of the healing of digital ulcerations, the second co-primary endpoint, there was no significant difference between bosentan and placebo.(a) ... primezone.com Encysive Pharmaceuticals Inc. Conference Call - Part 1. - Feb 14, 2005 The active control arm, bosentan, gave an improvement of 29.5 meters with a ... 1 patient each in the placebo, Thelin 100-milligram, and bosentan groups had ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Sildenafil Equal to Bosentan in Pulmonary Hypertension Therapy - Oct 1, 2005 Clinical Question: Is sildenafil (Viagra) more effective than bosentan (Tracleer) in the treatment of patients with class III pulmonary hypertension? ... AAFP News Now Effect of bosentan on skin fibrosis in patients with systemic... - Jun 1, 2007 Sponsored by Heinrich-Heine University, Duesseldorf. The purpose of this study is to evaluate the effect of bosentan treatment on skin fibrosis and its ... $4.95 - Journal of Drugs in Dermatology - ECNext Actelion Announces Successful Study With Tracleer(R) in Patients With... - Dec 18, 2006 The regimen for bosentan was an initial dose of 62.5 mg bid for four weeks for all ... The primary objective of the study was to demonstrate that bosentan ... RedOrbit Encysive Pharmaceuticals Announces New STRIDE-2 Data Presented at … - May 23, 2005 ..."We are very pleased with the clinical results of our second-generation, selective endothelin antagonist, whether compared to placebo or to bosentan, ... RedOrbit Septic Shock; Using bosentan during the later stages of septic shock:... - Mar 1, 2005 2005 MAR 1 - (NewsRx.com & NewsRx.net) -- Endothelin receptor antagonist bosentan improves survival in a murine caecal ligation and puncture model of septic ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Article: Bosentan aids scleroderma-associated PAH survival.( … - Jan 1, 2006 Bosentan aids scleroderma-associated PAH survival.(Dermatologic Therapy)(pulmonary arterial hypertension ) ... find Skin & Allergy News articles. Pay-Per-View - Skin & Allergy News - HighBeam Research Septic Shock; Using bosentan during the later stages of septic shock:... - Mar 4, 2005 2005 MAR 4 - (NewsRx.com & NewsRx.net) -- Endothelin receptor antagonist bosentan improves survival in a murine caecal ligation and puncture model of septic ... Pay-Per-View - Genomics & Genetics Weekly - Factiva, from Dow Jones Sitaxsentan better tolerated than bosentan as oral PAH therapy.( … - Aug 15, 2005 Sitaxsentan better tolerated than bosentan as oral PAH therapy.(Cardiovascular Medicine)(pulmonary arterial hypertension) ... find Family Practice News ... Pay-Per-View - Family Practice News - HighBeam Research 14 News, The Tri-State's News and Weather Leader-Combination … - Dec 1, 2006 In addition, none of the patients who received the bosentan-iloprost therapy experienced clinical deterioration over the course of the study. ... WFIE-TV New Ventavis Data Presented at CHEST Meeting. - Oct 31, 2005 Safety trends in patients receiving the combination of bosentan and Ventavis were consistent with those described with Ventavis monotherapy. ... Free with registration - PR Newswire - AccessMyLibrary.com Bosentan label change delineates cirrhosis risk.(Clinical Rounds) |... - Sep 1, 2006 Bosentan label change delineates cirrhosis risk.(Clinical Rounds) ... find Skin & Allergy News articles. ROCKVILLE, MD. -- The postmarketing safety program ... Pay-Per-View - Skin & Allergy News - HighBeam Research Pulmonary Hypertension Patients Improve From Combination Therapy - Dec 6, 2006 The researchers gave 32 patients both bosentan and inhaled iloprost, a prostacyclin analog. The remaining patients received bosentan and a placebo. ... Medical News Today - Medical News Today (press release) Bosentan performs well in IPF study.(Bosentan Use in Interstitial... - Jun 5, 2006 Swiss biopharmaceutical firm Actelion has announced that data from the Bosentan Use in Interstitial Lung Disease (BUILD) study provides a strong rationale ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Bosentan blocks scleroderma ulcers; does not hasten healing.( … - Feb 1, 2006 Bosentan blocks scleroderma ulcers; does not hasten healing.(Dermatologic Therapy) ... find Skin & Allergy News articles. SAN DIEGO -- A second randomized ... Pay-Per-View - Skin & Allergy News - HighBeam Research Cardiovascular Disease; Bosentan treatment improved functional... - Dec 27, 2005 2005 DEC 27 - (NewsRx.com) -- The first open prospective multicenter study of bosentan therapy shows improved functional status and exercise capacity for ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Diabetes Therapy; Bosentan decreases glucose levels without effects... - Apr 25, 2005 According to a study from Egypt, "Elevated plasma ET-1 levels have been reported in several conditions such as stress and diabetes. ... Pay-Per-View - Obesity & Diabetes Week - Factiva, from Dow Jones Diabetes Therapy; Bosentan decreases glucose levels without effects... - Apr 30, 2005 According to a study from Egypt, "Elevated plasma ET-1 levels have been reported in several conditions such as stress and diabetes. ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones GlobeNewswire, Inc. - News Room - May 24, 2005 Tracleer(R) (bosentan) is the first and only approved oral treatment for PAH (Class ... The results from TRAX show that the safety profile of bosentan is ... primezone.com … ; Results of drug trials for oral bosentan for scleroderma patients... - Jan 18, 2005 2005 JAN 18 - (NewsRx.com & NewsRx.net) -- Actelion Ltd (ATLN) announced the publication of the full results of the study with Tracleer (bosentan) in ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Sildenafil for pulmonary arterial hypertension, repackaged as Revatio - Nov 22, 2005 Another oral therapy, the dual endothelin receptor antagonist bosentan ... He does note, however, that there are more long-term data on bosentan in PAH than ... Medscape Actelion: pursuing Bosentan in IPF.(Wednesday, Nov. 30) - Dec 5, 2005 Actelion Ltd. discontinued studies of its dual endothelin receptor agonist bosentan in one indication, but intends to move forward with the drug in ... Pay-Per-View - BioWorld Week - Factiva, from Dow Jones … ; Results of drug trials for oral bosentan for scleroderma patients... - Jan 22, 2005 2005 JAN 22 - (NewsRx.com & NewsRx.net) -- Actelion Ltd (ATLN) announced the publication of the full results of the study with Tracleer (bosentan) in ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones … ; Results of drug trials for oral bosentan for scleroderma patients... - Jan 19, 2005 2005 JAN 19 - (NewsRx.com & NewsRx.net) -- Actelion Ltd (ATLN) announced the publication of the full results of the study with Tracleer (bosentan) in ... Pay-Per-View - Immunotherapy Weekly - Factiva, from Dow Jones Pulmonary Arterial Hypertension: The Race for the Most Effective … - Jun 4, 2005 It was the only therapy available until the approval of bosentan in late 2001. ... The improvements of 75 m with sildenafil and 59 m with bosentan in the ... RedOrbit Q3 2005 Myogen Earnings Conference Call - Final. - Nov 2, 2005 A total of 36 patients were enrolled in this trial, 92% of whom had discontinued Bosentan and 11% of whom had discontinued Sitaxsentan due to serum ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com The labeling for bosentan (Tracleer, Actelion) was revised to include... - May 1, 2006 The labeling for bosentan (Tracleer, Actelion) was revised to include notification of cases of hepatotoxicity that were reported with the agent. ... $9.94 - Formulary - Alacra Store … : Skin health boosted and maintained with bosentan.(News) - Skin & ... - Aug 1, 2005 Skin health boosted and maintained with bosentan.(News) ... find Skin & Allergy News articles. VIENNA -- The endothelin receptor antagonist bosentan, ... Pay-Per-View - Skin & Allergy News - HighBeam Research bosentan Actelion clinical data (pulmonary hypertension).( … - Feb 7, 2005 ...a total of 245 patients. Results showed that survival in the bosentan-treated patients was 96% at one year and 89% at two years compared with US National ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones bosentan Actelion marketed, Japan (pulmonary hypertension).(Brief … - Jun 20, 2005 Actelion announced on 8 June 2005 that bosentan (TRACLEER) has been launched in Japan for the treatment of all forms of pulmonary arterial hypertension (WHO ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Article: Bosentan label changes highlight monthly liver function … - May 1, 2006 Reported cases of hepatotoxicity associated with bosentan therapy have prompted changes to the pulmonary arterial hypertension drug's prescribing ... Pay-Per-View - Skin & Allergy News - HighBeam Research … surveillance system confirms Bosentan's safety.(Cardiovascular... - Feb 1, 2006 STOCKHOLM -- An Internet-based postmarketing surveillance program has provided reassurance regarding the long-term safety of bosentan (Tracleer) in routine ... Pay-Per-View - Family Practice News - HighBeam Research CoTherix reports positive clinical data from STEP study. - Mar 8, 2005 The analysis of this study showed that the combination of Ventavis (iloprost) Inhalation Solution added to Tracleer (bosentan) therapy was well tolerated ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com GlobeNewswire, Inc. - News Room - Feb 1, 2005 Outcome in patients receiving first-line bosentan therapy was compared to patient ... The study "Survival with first-line bosentan in patients with primary ... primezone.com Sildenafil And Atorvastatin Added To Bosentan As Therapy For … - Apr 15, 2006 Sildenafil And Atorvastatin Added To Bosentan As Therapy For Pulmonary Hypertension Sildenafil And Atorvastatin Added To Bosentan As Therapy For Pulmonary ... Subscription - Internet Journal of Pulmonary Medicine - EBSCO Publishing Pulmonary Arterial Hypertension; Company reports positive clinical... - Apr 4, 2005 The analysis of this study showed that the combination of Ventavis (iloprost) Inhalation Solution added to Tracleer (bosentan) therapy was well-tolerated ... Pay-Per-View - Clinical Trials Week - Factiva, from Dow Jones … Hypertension Study Published in The Lancet Concludes That Bosentan... - Jun 20, 2008 In contrast, treatment with bosentan significantly delayed PAH progression ... The findings of EARLY indicate that treatment with bosentan may be beneficial ... Pay-Per-View - PR Newswire - HighBeam Research … results after addition of sildenafil in idiopathic PAH patients on... - Aug 1, 2006 The patient was placed on bosentan 62.5 mg bid and later increased to 125 bid ... On bosentan she improved to a functional class II with a better 6MW score. ... Free with registration - Southern Medical Journal - AccessMyLibrary.com … Highlights Strong Rationale for a Morbidity/Mortality Study with... - May 23, 2006 As previously communicated in November 2005, bosentan did not have a positive ... The use of bosentan in the study was well tolerated with no unexpected ... primezone.com Press Release: Tracleer(R) Shows Clinical Benefit as Combination … - Oct 23, 2007 COMPASS-1 (Effects of Combination Of bosentan and sildenafil versus ... Article: Bosentan Improves Quality of Life and Prognosis for Patients with ... ... Pay-Per-View - PR Newswire - HighBeam Research Myogen alters ambrisentan guidance. - Feb 14, 2005 ...penetration of Actelion's Tracleer (bosentan) and Pfizer's Revatio (sildenafil). Other clinical trials are also competing for this group of patients. ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Encysive stock moves up 12 percent on Thelin data.(Tuesday, February ... - Feb 21, 2005 Tracleer (bosentan) therapy served as the control arm of the trial Approved in 2001, the product was developed by Allschwil, Switzerland-based Actelion Ltd. ... Pay-Per-View - BioWorld Week - Factiva, from Dow Jones Mixed trial results for Actelion's Tracleer.(Brief Article) - Dec 5, 2005 Swiss drugmaker Actelion says that, in recent trials of Tracleer (bosentan), the firm's dual endothelin receptor antagonist, in patients suffering from ... $4.95 - Pharma Marketletter - ECNext Drépanocytose : un médicament déjà disponible pourrait être utile - Apr 4, 2008 ...de ces crises et démontré sur des souris le potentiel thérapeutique d'une molécule utilisée contre l'hypertension artérielle pulmonaire, le bosentan. ... Le Point New drug for PAH - Jul 4, 2005 The clinical data to date suggest that patients with PAH taking bosentan don't deteriorate any further, but those taking sitaxsentan show statistically ... Medscape Sitaxsentan proves effective in pulmonary arterial hypertension: the ... - Aug 15, 2005 Bosentan blocks both receptor types, while sitaxsentan is extremely selective ... Moreover, bosentan has been associated with relatively high rates of liver ... Free with registration - Family Practice News - AccessMyLibrary.com New salvage therapy for PAH: oral sitaxsentan.(Rx)(pulmonary arterial... - Jul 15, 2005 Unlike twice-daily bosentan, sitaxsentan can be given once daily because it is ... Overall, 35 of the patients in the study had discontinued bosentan ... Free with registration - Internal Medicine News - AccessMyLibrary.com Sitaxsentan Broadens Treatment Options for Pulmonary Arterial … - Sep 23, 2005 To compare sitaxsentan to bosentan, the study design also included an ... The standard dose of bosentan for this indication is 62.5 mg twice daily for the ... Medscape DJ HUGIN NEWS/Tracleer® (Bosentan) erhält EU-Zulassung für die … - Aug 4, 2008 Corporate news- Mitteilung verarbeitet und übermittelt durch Hugin. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. ... financial.de Fewer Liver Function Abnormalities Seen With Sitaxsetan in Pulmonary ... - Nov 2, 2005 Bosentan is a dual nonselective antagonist of the endothelin receptors ETa ... "Bosentan therapy has been complicated by abnormal liver function tests in a ... DG News |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |